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INTRODUCTION
The  rate of success in the treatment of acute lymphoblastic leukemia 
(ALL) has increased steadily since the 1960s. The five-year event-free 
survival  rate  is  nearly  80  percent  for  children  with ALL  and 
approximately 40 percent for adults.(1,2) Up to 80% of pediatric patients 
with  acute  lymphoblastic  leukemia  (ALL)  can  be  cured  if  intensive 
therapy is applied. Severe side effects may be encountered in all patients 
of  which,  however,  only  the  minority  is  life-threatening.  The  leading 
cause of failure in childhood ALL is still recurrence of disease.Deciding 
about  treatment  protocol  after  risk  stratification  as  followed by BFM 
group is aimed at reducing relapses as well as treatment morbidity. One 
of  the  important  components  is  the  introduction  of  High  dose 
Methotrexate  in  the  consolidation  phase.  This  combined  with  cranial 
radiotherapy in High risk group is postulated to prevent CNS relapses.
(5,12).
Methotrexate (MTX) is one of the most widely used anti-cancer agents, 
and  administration  of  high-dose  methotrexate  (HDMTX) followed  by 
leucovorin (LV) rescue is an important component in the treatment of a 
variety  of  childhood  and  adult  cancers. HDMTX  can  be  safely 
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administered  to  patients  with  normal  renal function  by  the  use  of 
alkalinization,  hydration,  and  pharmacokinetically guided  LV  rescue. 
(15).Despite  these  measures,  HDMTX-induced  renal dysfunction 
continues to occur in approximately 1.8% of patients with osteosarcoma 
treated  on  clinical  trials.  Prompt  recognition and  treatment  of  MTX-
induced  renal  dysfunction  are  essential to  prevent  potentially  life-
threatening  MTX-associated  toxicities, especially  myelosuppression, 
mucositis, and dermatitis.(26,27).
Since the initiation of monitoring of MTX plasma concentrations and 
appropriate alterations in leucovorin dosage and hydration, the frequency 
of  serious  toxicity  has  been reduced and toxic  deaths  following HD-
MTX  have  been  virtually  eliminated.  This  is  an  observational 
nonrandomized study of clinical and biochemical variables to identify 
the risk factors  associated with high-dose MTX therapy.              
There are limited data of  complications resulting from treatment of ALL 
incorporating  high dose Methotrexate from  developing countries like 
India, wherein besides the major risk factors, pharmacokinetic variables, 
socioeconomic factors ,and other environmental factors also might play 
an important role.
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AIMS
• To  study  the  toxicity  profile  of  high  dose  methotrexate  in 
treatment of Acute Lymphoblastic Leukemia
• To compare between tolerability of 3gm/m2 and 5 gm/ m2 of high 
dose methotrexate
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REVIEW OF LITERATURE
Background and Rationale
Acute  Lymphoblastic  leukemia  has  a  cure  rate  nearing  80%  in  the 
developed world.  Patients are broadly classified and treated as standard 
risk or high risk ased on age and white blood cell count (WBC).(1,2) 
Despite almost constant progress in the treatment of this disease, there 
are  major  concerns  about  the  predictive  values  of  current  prognostic 
factors and the universal intensification of therapy.(3,4) .
Prognostic factors in ALL
Risk factor Favorable Unfavorable
Age 1 and 9 years <1 or >9 years
Gender Female Male
WBC count at diagnosis <50,000/mm3 50,000/mm3
DNA index >1.16 1.16
Chromosome number per 
leukemic cell
>50 <45, especially 
24-28
Induction response to prednisone 
on day 8
No peripheral 
blasts
Peripheral blasts
CNS status CNS 1 CNS 2 or 3
Cytogenetics Trisomies 4 
and 10
t(4;11), t(9;22)
Molecular genetics TEL-AML1 MLL gene 
rearrangements
Immunophenotype Precursor B T cell, mature B cell
Strategies responsible for the improvement in results include:
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1) Prolongation  of  treatment  with  two  or  more  sequential 
combinations of multiagent chemotherapy, 
2) CNS prophylaxis 
3) Stratification of  patients  according  to  prognostic  factors  that 
predict risk of relapse,
4) Risk-based intensification of therapy, 
5) Large, controlled and usually randomized clinical trials. 
Risk Directed Therapy in ALL
A breakthrough in the treatment of children with acute lymphoblastic 
leukemia  (ALL)  came  with  the  introduction  of  treatments  that could 
penetrate the CNS. Trials in the late 1960s and early 1970s established 
that  children  who  received  effective  CNS-directed therapy  had 
substantially  superior  event-free  survival  (EFS) and  overall  survival. 
(4,5)The treatments used were initially craniospinal irradiation and then 
cranial irradiation, usually at a dose of 24 Gy, with short-term intrathecal 
therapy.  However,  with long-term  follow-up  of  large  numbers  of 
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children,  it  became apparent  that  there  were  late  adverse  effects, 
including  growth and  endocrine  problems,(6,7)  an  increased  risk  of 
developing secondary  tumors,(8,9)  and  possible  neuropsychological 
sequelae.(10,11)  With  the  development  of  alternative  CNS-directed 
strategies,  including  variations  in  the  radiotherapy  dose  and 
combinations  of  intrathecal  treatment  and  high-dose  intravenous 
methotrexate, the question is now whether alternatives expected to have 
fewer such side effects might be as effective for disease control. 
BFM 86 PROTOCOL
The trial ALL-BFM 86 is the sixth multicenter trial in childhood acute 
lymphoblastic  leukemia  ,conducted  by  the  Berlin-Frankfurt-Munster 
(BFM) group. 928 evaluable patients were enrolled in study ALL-BFM 
86. The estimated 6-year EFS was 72% for the whole study population 
including all subsets of childhood ALL. Patients with T-cell ALL had a 
favorable EFS with this intensive treatment regimen The contribution of 
HD-MTX to the overall treatment results of the trial is difficult to judge. 
A  major  contribution  of  HD-MTX   as  a  24-hour  infusion  may  be 
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protection of the CNS because cytotoxic steady-state concentrations are 
achieved in the cerebrospinal and are boosted by an intrathecal  MTX 
application.  Only  1.8%  of  the  patients  suffered  from  isolated  CNS 
relapses.
METHOTREXATE
Methotrexate (MTX), a classical antifolate,  is one of the most widely 
used and studied anticancer agents. Unlike other anticancer agents, MTX 
can be safely administered over a wide dose range, ranging from 20 mg/
m2 per  week  in  maintenance chemotherapy  for  acute  lymphoblastic 
leukemia  and when combined with leucovorin (LV) rescue, to doses of 
1,000–33,000 mg/m2 (13).  The  latter,  termed high-dose  methotrexate 
(HDMTX) is usually administered as a prolonged i.v. infusion and is an 
important component in the treatment regimens for a variety of cancers, 
including  acute lymphoblastic  leukemia,  lymphoma,  osteosarcoma, 
breast cancer, and head and neck cancer (14,15). HDMTX can be safely 
administered  to  patients  with  normal  renal  function  by  vigorously 
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hydrating and alkalinizing the patient to enhance the solubility of MTX 
in urine and through the use of pharmacokinetically guided LV rescue to 
prevent potentially lethal MTX toxicity. 
MTX PHARMACOLOGY 
Knowledge  of  MTX’s  mechanism  of  action  and  metabolism are 
important  for  understanding  MTX-associated  toxicities  and treatment. 
MTX  enters  the  cell  via  the  reduced  folate  carrier and  undergoes 
polyglutamation  catalyzed  by  folyl-polyglutamate synthetase.  Once 
polyglutamated, MTX is retained in cells for prolonged periods of time. 
Methotrexate and its polyglutamates block de novo nucleotide synthesis 
primarily  by  depleting  cells of  reduced  tetrahydrofolate  cofactors 
through inhibition of dihydrofolate reductase (DHFR) (Fig. 1 ) (17.) 
MTX polyglutamates and dihydrofolates that accumulate as a result of 
DHFR inhibition also inhibit thymidylate synthase and other enzymes 
involved in the purine biosynthetic pathway. 
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Figure 1. Folate pathway. Sites of action of methotrexate (MTX) and of 
the rescue agents leucovorin and thymidine. MTX primarily inhibits 
dihydrofolate reductase (DHFR). This results in the depletion of reduced 
folates (FH4), which are required for deoxythymidine monophosphate 
(dTMP) synthesis from deoxyuridine monophosphate (dUMP), and in 
accumulation of dihydrofolates (FH2), which inhibit purine synthesis. 
The MTX rescue agent leucovorin restores the reduced folate pool after 
conversion to its active metabolite 5-methyltetrahydrofolate (5-CH3-
FH4). Thymidine is directly converted to thymidine monophosphate by 
the enzyme thymidine kinase (TK).
Similar  to  other  antimetabolites,  critical  determinants  of  MTX 
cytotoxicity  are  not  only  drug  concentration  but  also  duration of 
exposure. High concentrations of MTX may be well tolerated for brief 
periods of time, whereas prolonged exposure to low concentrations can 
result  in  life-threatening  toxicity.  The type  of  toxicity  observed  with 
MTX is also a function of this concentration–time dependence. Exposure 
to millimolar concentrations of MTX for minutes to hours may lead to 
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acute renal, central nervous system, and liver toxicity; exposure to MTX 
concentrations as low as 0.01 and 0.005 µM for >24 hours may result in 
bone marrow and gastrointestinal epithelial toxicity, respectively(18). 
Following  administration  of  HDMTX,  two  metabolites,  7-hydroxy-
methotrexate (7-OH-MTX)  and  2,4-diamino-N10-methylpteroic  acid 
(DAMPA), are observed in plasma. Within 12–24 hours of the start of a 
HDMTX infusion, the plasma concentration of 7-OH-MTX, formed by 
the action of the enzyme aldehyde oxidase, exceeds the concentration of 
MTX.Intracellular polyglutamation of 7-OH-MTX results in prolonged 
retention and enhanced cytotoxicity. DAMPA, a minor, inactive(19,20) 
metabolite of MTX, accounting for <5% of the total dose of drug that is 
excreted in urine, is presumably formed from MTX that is excreted into 
the intestinal tract, hydrolyzed by bacterial carboxypeptidases, and then 
reabsorbed.
Methotrexate Induced Renal Dysfunction
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As MTX is  primarily cleared by  renal  excretion,  MTX-induced renal 
dysfunction  leads to  delayed  elimination  of  MTX,  and  the  resulting 
sustained, elevated plasma MTX concentration may lead to ineffective 
rescue by  LV  and  a  marked  enhancement  of  MTX’s  other 
toxicities.Since the introduction of HDMTX with LV rescue more than 
25 years ago by Djerassi et al.(16), the ability to safely administer this 
regimen  to  patients  has  improved,  and  there  have  been a number  of 
advances in the treatment of HDMTX-induced renal dysfunction over 
the past  20 years.  The etiology of MTX-induced renal  dysfunction is 
believed to be mediated by the precipitation of MTX and its metabolites 
in the renal tubules  or via a direct toxic effect of MTX on the renal 
tubules.  More  than  90% of  MTX is  cleared by the kidneys.  MTX is 
poorly  soluble  at  acidic  pH,  and its  metabolites,  7-OH-MTX  and 
DAMPA, are six- to tenfold less soluble than MTX, respectively. An 
increase in the urine pH from 6.0 to 7.0 results in a five- to eightfold 
greater solubility of MTX and its metabolites(22) .Several drugs have 
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been associated with increased toxicity when coadministered with MTX. 
The most significant interactions involve agents that interfere with MTX 
excretion, primarily by competing for renal  tubular  secretion,  such as 
probenecid,  salicylates, penicillins,  and nonsteroidal  anti-inflammatory 
agents.MTX-induced  renal  dysfunction  results  in  sustained,  elevated 
plasma  MTX  concentrations,  which  in  turn  may  lead  to  ineffective 
rescue by  LV and a  marked enhancement  of  MTX’s other  toxicities, 
especially myelosuppression, mucositis, hepatitis, and dermatitis. 
Vomiting and diarrhea during or shortly after the administration of MTX 
have been observed in patients who developed MTX toxicity, but the 
majority of patients with renal dysfunction are initially asymptomatic, 
and most present with nonoliguric renal dysfunction . Although the risk 
for  MTX  toxicity is  dependent  upon  the  dose  and  schedule  of 
administration,  plasma MTX concentrations  should  be  1.0  µM at  42 
hours  after the  start  of  the  HDMTX  infusion,  and  plasma  MTX 
concentrations 10 µM at this time point are associated with a high risk 
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for the development of toxicities (24,25). 
Prevention and management of HDMTX toxicity 
The  guiding  principles  for  prevention  of  HDMTX  toxicity,  namely 
maintaining  urine  output,  urinary  alkalinization,  monitoring  serum 
creatinine,  electrolytes,  and  plasma  MTX  concentrations,  and 
pharmacokinetically -guided leucovorin rescue, are also the cornerstones 
of management for patients who develop early signs of renal dysfunction 
and delayed MTX elimination.
1) Hydration and urinary alkalinization
Maintaining adequate hydration and urine output are essential for rapid 
clearance  of  MTX.  Most  protocols  recommend  at  least  2.5  to  3.5 
liters/m2 of IV fluid hydration per day, starting four to 12 hours prior to 
the initiation of the MTX infusion.
The pH of the urine should be measured at baseline. MTX precipitates in 
acid  urine;  maintaining  the  urine  pH  7.0  or  higher  increases  MTX 
solubility,  prevents  drug precipitation in renal  tubules,  and drastically 
decreases the chance of renal damage. In clinical practice, it is customary 
to  begin  the  MTX  infusion  only  after  the  urine  pH  is  ≥7.0,  and  to 
maintain it in this range until plasma MTX levels have declined to less 
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than 0.1 microM.
Urinary alkalinization is most easily accomplished by adding ampules 
(amps) of  sodium bicarbonate to each liter of IV fluid hydration. This 
accomplishes both fluid hydration and urinary alkalinization.
A typical  choice is  IV D5W with 2 to  3  amps (100 to  150 meq)  of 
sodium bicarbonate per liter, administered by continuous infusion at 125 
to  150  mL/hour.  A  cation  concentration  of  80.5  meq/L  is  roughly 
equivalent to one-half normal saline. The amount of bicarbonate in each 
liter and the IV fluid composition can then be modified according to the 
urine pH, and serum sodium. If only one amp of bicarbonate is added to 
each liter of IV fluid, physicians should be aware that the resultant fluid 
will be hypotonic if D5W is used
2) Leucovorin administration 
Leucovorin rescue should be started within 24 to 36 hours of the start of 
the MTX infusion. A variety of dosing schedules have been published, 
but most administer 10 mg/m2 IV or 15 mg/m2 orally every six hours 
until plasma MTX levels are less than 0.05 to 0.1 micromol/L. The size 
and number of leucovorin doses do not appear to be critical in patients 
who have normal MTX clearance(27). Even doses of 10 to 15 mg/m2 are 
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often in excess of those required to achieve rescue in such patients. In 
contrast,  higher  concentrations  of  leucovorin  are  needed  if  rapid 
elimination of MTX is compromised by renal insufficiency.
Early studies conducted in the 1970s revealed that the following drug 
levels after MTX infusion indicated a high risk for bone marrow and 
gastrointestinal mucosal toxicity (28,29)
Levels above 5 to 10 microM at 24 hours
Levels above 0.9 to 1 microM at 48 hours
Levels above 0.1 microM at 72 hours
Leucovorin in patients with delayed elimination and prolonged elevated 
plasma MTX levels is as follows(Uptodate)
Plasma methotrexate (MTX) 
level
Leucovorin dose and/or schedule 
adjustment
24 hours
>1-5 micromolar 25-50 mg/m2 every 6 hours IV
10 micromolar 50-100 mg/m2 q 6 hours IV
48 hours
1 micromolar 50-100 mg/m2 q 6 hours IV
10 micromolar 100-200 mg/m2 q 3-4 hours IV
72 hours
0.1-0.9 micromolar 50-100 mg/m2 every 6 hours IV
1 micromolar 50-100 mg/m2 q 3-4 hours IV
Alternative  rescue  techniques  have  been  utilized  in  an  attempt  to 
enhance  MTX  clearance  and/or  minimize  severe  systemic  toxicity. 
20
These include extracorporeal removal of MTX by means of peritoneal 
dialysis,  hemodialysis,  hemoperfusion,  and/or  charcoal  hemofiltration 
administration  of  leucovorin in  conjunction  with  thymidine,  and 
administration of the metabolizing enzyme carboxypeptidase G2(30,31)
Oral Mucositis 
Oral mucositis is a common problem after high-dose methotrexate (HD-
MTX) treatment. Seveal studies have been carried out to identify factors 
associated with the development of mucositis in children with ALL who 
had no delayed elimination of methotrexate (MTX)). Pharmacokinetic 
studies of MTX and the metabolite 7-hydroxymethotrexate (7-OHMTX) 
in plasma and saliva is an indicator of risk for mucositis.(26). Grade of 
mucositis   was  found  to  correlate  significantly  with  low  systemic 
clearance of MTX during the infusion and a low p-7-OHMTX/p-MTX 
ratio at 66 hours after the start of infusion. The MTX concentration in 
saliva didnot show any correlation with the development of mucositis. 
The  present  conventional  criteria  for  high-risk  MTX  concentrations 
might need to be reevaluated because a high percentage of patients still 
21
suffer from oral toxicity despite "normal" elimination. A reduced ratio 
between  the  simultaneous  concentrations  of  7-OHMTX and  MTX in 
plasma may be a possible mechanism of this unpredictable oral toxicity.
Hepatotoxicity 
MTX has the potential for hepatotoxicity at all doses. The association 
between  MTX  and  hepatic  dysfunction  has  been  studied  most 
extensively  in  patients  receiving  chronic  oral  low-dose  MTX. 
Hepatotoxicity can be manifested as a mild transaminitis, but patients are 
at risk for fibrosis and cirrhosis when the total dose exceeds 1.5 to 2 
grams. 
HDMTX can cause an acute elevation in the serum transaminases from 
two  to  twenty-fold  normal  levels,  even  in  patients  who  receive 
leucovorin rescue. Acute transaminitis occurs in as many as 60 to 80 
percent of patients, and typically resolves spontaneously within one to 
two weeks. If the level of alanine transferase (ALT) has not returned to 
less than 180 IU/L by the beginning of the next treatment cycle, the next 
dose should be reduced and/or delayed.
Rarely, HDMTX causes a temporary elevation in serum bilirubin, which 
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usually normalizes within a few days. Subsequent cycles do not require 
dose reduction unless the peak serum bilirubin level  exceeds 3 mg/dl 
(32).Among patients receiving IV MTX for treatment of cancer, hepatic 
fibrosis  (with a  subsequent  risk  for  hepatocellular  cancer)  is  reported 
only rarely. All cases have been in children receiving MTX for acute 
lymphoblastic leukemia. 
FEBRILE NEUTROPENIA 
Neutropenia.     When  the  neutrophil  count decreases  to  <1000 
cells/mm3, increased susceptibility to infection can be expected, with the 
frequency  and severity inversely  proportional  to  the neutrophil  count. 
Patients with neutrophil  counts  of <500 cells/mm3 are  at considerably 
greater risk for infection than are those with counts of <1000 cells/mm3, 
and patients with counts of  100 cells/mm3  are at greater risk than are 
those with counts of <500 cells/mm3.
The criteria for defining a infection related fever in the presence of grade 
IV neutropenia(lancet) ( absolute neutrophil count < 0.5 x 109 / L ) are
1. Oral temperature of > 38˚C on at least one occasion, associated 
with a clinical focus of infection.
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2. Oral temperature >38˚C but < 39˚C sustained upto 12 hrs in the 
absence of other non-infectious pyrogenic processes and without a 
clinical focus of infection
3. Oral temperature >39˚C on at least one occasion with chills but in 
the absence of other non-infectious pyrogenic processes 
In  addition  to  the number  of  circulating  neutrophils, the  duration  of 
neutropenia is an important determinant of infection. A low nadir in the 
neutrophil count  and  protracted  neutropenia (i.e.,  neutrophil  count  of 
<500  cells/mm3 for  10 days)  are  major  risk factors  for  impending 
infection (33).
Recommendations for evaluation.
Initial evaluation should consist of a thorough physical examination; a 
complete blood cell count; measurement of serum levels of creatinine, 
urea nitrogen, and transaminases; and culture of blood samples (obtained 
from a peripheral vein and/or a catheter). A chest radiograph is indicated 
for  patients  with respiratory  signs  or  symptoms or  if  outpatient 
management is planned.
Specimens should be obtained immediately for culture for bacteria and 
fungi. If  a  central  venous access  device  is  in place,  some authorities, 
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including the new "IDSA Guidelines for the Management of Intravascular 
Catheter Related  Infections"(34), recommend  that  1  set of  blood 
samples be obtained for culture from the device lumen(s) as well as from 
a peripheral vein. Other investigators believe that culture only of a blood 
sample obtained  from  a  central venous  catheter  is  adequate [idsa). 
Quantitative  blood cultures,  although  not  necessarily recommended 
routinely for all patients, may be helpful for those suspected of having a 
catheter-related infection, for whom specimens obtained from a central 
venous catheter and a peripheral vein should be compared 
TREATMENT
The initial regimen chosen should be a broad spectrum covering majority 
of the Gram negative and Gram positive organism either in the form of 
monotherapy of polymicrobial therapy. This initial  regimen should be 
continued  until  5  days  unless  the  clinical  condition  deteriorates 
substantially. The observations of Elting and colleagues, that the median 
time to clinical response of febrile neutropenia due to bacterial infections 
was 5-7 days after introduction of antibiotics,  must always be kept in 
mind.(35)
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The second important point is the duration of therapy; most patients with 
febrile neutropenia do not have documented infections, so decision on 
the duration of treatment cannot be made on the basis of sterilization of 
cultures or presence of specific organisms
Pizzo  and  colleagues  suggested  that  antibacterial  therapy  should  be 
continued  until  neutropenia  resolves,  though  there  is  lack  of  strong 
evidence that shorter duration would lower the risks of development of 
fungal  infections,  antibiotic  resistance,  and  drug-related  toxic  effects.
(36)
Selection of antibiotics was based on the hospital Antibiotic Policy
Table 1:
1st line : Cefaperazone/sulbactam+ Amikacin
2nd line  : Piperacillin+ Tazobactam + Amikacin
3rd line  : Meropenam/Imipenem
Gram+ive: Vancomycin
Antifungal: Amphoterecin  B
USE OF COLONY-STIMULATING FACTORS IN TREATMENT
Hematopoietic growth factors have been studied as adjunctive therapy to 
antimicrobial  therapy for  febrile  neutropenic  patients in  several 
randomized, controlled trials (37,38). These studies show that G-CSF or 
granulocyte-macrophage colony-stimulating factor  used as part of the 
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treatment  of febrile  neutropenic  patients  can consistently  shorten  the 
duration of  neutropenia,  but  these agents  have  not  consistently and 
significantly  reduced  other measures  of  febrile  morbidity, including 
duration of fever, use of anti-infectives, or costs of management of the 
febrile  neutropenic  episode. No study has  demonstrated a decrease  in 
infection-related mortality  rates.  The  2001 update  of  the  American 
Society of Clinical Oncology guidelines recommends against the routine 
use of hematopoietic growth factor in uncomplicated cases of fever and 
neutropenia.
Dose intensity of 6 Mercaptopurine
Since  their  introduction  to  leukemia  treatment  in  the  1950s, the 
thiopurines mercaptopurine and thioguanine have played an essential role 
in  treatment  protocols  for  ALL.  TPMT  is  a  cytosolic  enzyme 
ubiquitously expressed  in  the  human  body  and  catalyzes  the  S-
methylation of  thiopurines.  The  TPMT  locus  is  subject  to  genetic 
polymorphism.  To  date  20  variant  alleles  (TPMT*2-*18)  have  been 
identified, which With regard to treatment outcome in childhood ALL, 
Lennard and colleagues(50) described in 1990 a higher relapse rate in 
children with lower thioguanine nucleotide concentrations measured in 
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erythrocytes and suggested a substantial role for genetically determined 
TPMT  activity  in  the  predisposition  to  the  cytotoxic effects  of 
mercaptopurine  and,  consequently,  ALL outcome.  Their hypothesis  is 
supported by the work of Relling and colleagues(51) who demonstrated 
in a study of 182 children with ALL that mercaptopurine dose intensity 
was the strongest  predictor  of  outcome are  associated with decreased 
activity compared with the TPMT*1 wild-type allele., The association of 
TPMT genotype with minimal residual disease levels before and after 
application  of  a  4-week  cycle  of  mercaptopurine  during induction 
consolidation  treatment  in  BFM protocols  thus  having  an  impact  on 
outcome has also been reported(52).
Neurotoxicity following HDMTX
The incidence  of  various  neurological  events  following lntrathecal  or 
intravenous high dose  Methotrexate is estimated around 4-15%
(1).Three distinct clinical patterns of neurotoxicity have been observed 
(a)  an  acute  toxicity,  occurring  within  hours  of  IT  chemotherapy, 
probably resulting from chemical  arachnoiditis;  (b)  sub acute  toxicity 
occurring  within  days  or  weeks,  and  characterized  by  symptoms  of 
seizures, transient paresis, or cerebellar abnormalities; and (c) a delayed 
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leukoencephalopathy form that  is  more  commonly  observed when IT 
MTX is used with cranial irradiation (53).
The  mechanism  of  methotrexate  induced  neurotoxicity  is  poorly 
understood. Both high-dose intravenous MTX and intrathecal MTX are 
proposed to have association with demyelination, white matter necrosis, 
loss of  oligodendroglia, axonal swelling, microcystic encephalomalacia, 
and atrophy relatively selective for the deep cerebral white matter (54). 
An  altered  myelin  metabolism  disturbance  induced  by  Mtx  (55)  or 
elevated  levels  of  homocysteine  and  its  excitatory  amino  acid 
neurotransmitter  metabolites  (homocysteic  acid  and  cysteine  sulfinic 
acid) may mediate, in part, methotrexate-associated neurotoxicity (56). 
The  absence  of  significant  imaging  abnormalities  has  raised  the 
possibility of cyotoxic edema.
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SUBJECTS AND METHODS
Inclusion criteria
1. Patients  undergoing  BFM  86  protocol  treatment  at  Cancer 
Institute,Chennai
2. Age group:3- 25 years
3. Patients  who  have  attained  complete  remission  after  induction 
chemotherapy 
Exclusion criteria
1) Pre existing renal dysfunction-Serum Creatinine value >1.4 mg/dl 
OR Creatinne clearance less than 70 ml/minute
2) History  of  any neurological disorder including epilepsy
3) CNS involvement at presentation as defined by the ROME criteria
The study population included 60 patients who were  analysed  in   two 
groups  ,  Group  A  (30  patients  who  received  3gm/m2 of  high  dose 
methotrexate) and Group B (30 patients who were treated with 5 gm/ m2 
of high dose methotrexate). 
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BFM 86 protocol 
Consolidation treatment is with High dose Methotrexate,4 doses given 
on days 8,22,36 and 50. 6MercaptoPurine(6 MP) is started at 25 mg/m2 
on day 1 and continued till day 56.4 doses of intrathecal methotrexate 
are also given along with HDMTX.  .HDMTX was given as a 24 hour 
infusion  with  3  litres  /m2   /day  of  intravenous  hydration  and 
alkalanisation. HDMTX was given only if urinary pH was determined as 
alkaline  prior to infusion. Creatinine clearance was checked prior to 1 st 
dose of  HDMTX .Urea and creatinine  were monitored daily.  Serum 
Methotrexate  levels  were  done  at  48  and  72  hours  after  starting  of 
infusion. Leucovorin rescue was started at 48 hours at 15 mg/m2  iv q 6 
th hourly and continued for a total of 16 doses ,unless there was any 
renal toxicity necessitating dose adjustment .
Following  HDMTX  infusion,  toxicities  like  mucositis, 
myelosuppression, Liver Function Test abnormalities were noted ,graded 
and managed appropriately .GCSF and blood component support  given 
as  required.  Febrile  episodes  were  treated  as  per  protocol.6  MP was 
continued  unless  there  was  Grade  3/4  myelosuppression,  febrile 
neutropenia or transaminitis.   
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Methotrexate Assay
Emit Methotrexate assay, which is a homogenous enzyme immunoassay 
intended for use in the quantitative analysis of methotrexate in human 
serum or plasma was used. With this assay, samples containing 0.3-2600 
micromol/L  can  be  analysed.  Primary  protocol  can  analyse  up  to  2 
micromol/L methotrexate and those more than that can be brought within 
range  of  standard  curve  by  serial  dilution.Each  assay  requires  50 
microlitre of serum or plasma. Whole blood cannot be used. Acceptable 
anticoagulants are heparin, EDTA and oxalate. Serum or plasma is to be 
kept at 2-8degree centigrade and protected from sunlight. Leucovorin or 
Trimethoprim   do  not  interfere  with  this  assay  at  maximum 
pharmacological or physiological concentrations.(Source-Product insert 
of Dade Behring Syva Emit Methotrexate Assay)t
MTX excretion 24 hours 48 hours 72 hours
Normal 10 µ mol/L 1 µ mol/L < 0.2 µ mol/L
Delayed late > 0.2 µ mol/L
Delayed early 50 µ mol/L 5 µ mol/L
Leucovorin dose
Normal 15 mg/m2 q 6H for 16 doses
Delayed late 15 mg/m2  q 6H till < 0.05 µ mol/L
Delayed early 150 mg/m2  q 3H till < 1 µ mol/L
    15 mg/m2  q 3H till < 0.05 µ mol/L
Statistical Methods: Descriptive statistical analysis has been carried out 
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in the present study. Results on continuous measurements are presented 
on Mean ± SD (Min-Max) and results on categorical measurements are 
presented  in  Number  (%).  Significance  is  assessed  at  5  %  level  of 
significance.  ,Student t test ( two tailed, independent)  has been used to 
find the significance of study parameters on continuous scale between 
two  groups  Inter  group  analysis)  and  Student  t  test  (two  tailed, 
dependent) has been used to find the significance of study parameters on 
continuous scale with in each group. Chi-square/ Fisher Exact test has 
been used to find the significance of study parameters  on categorical 
scale between two groups(39,40,41)
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4. Student  t-test for  paired comparisons 
Statistical software: The Statistical software namely SPSS 15.0, Stata 
8.0, MedCalc 9.0.1 and Systat 11.0 were used for the analysis of the data 
34
RESULTS
Table 1: Comparison of age distribution of patients studied
Age in 
years
Group A Group B Total
No % No % No %
Up to 5 12 40.0 10 33.3 22 36.7
6-10 6 20.0 7 23.3 13 21.7
11-15 9 30.0 8 26.7 17 28.3
16-20 3 10.0 5 16.7 8 13.3
Total 30 100.0 30 100.0 60 100.0
Mean ± SD 10.57±7.21 10.73±7.39 10.65±7.24
Samples are age matched with P=0.730
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Table 2: Comparison of gender distribution of patients studied
Gender 
Group A Group B Total
No % No % No %
35
Male 20 66.7 15 50.0 35 58.3
Female 10 33.3 15 50.0 25 41.7
Total 30 100.0 30 100.0 60 100.0
Samples are gender matched with P=0.190
Table 3: Comparison of Total count  of patients studied
Total  
count 
Group A Group B Total
No % No % No %
<50000 20 70 19 65.5 38 67.9
>50000 10 30 11 34.5 18 32.1
Total 30 100.0 30 100.0 56 100.0
Group A Group B
Table 4: Comparison of average number of days to complete the 
protocol (C – Consolidation)
Phases Group A Group B P value
C1 17.83±5.29 16.40±3.98 0.241
C2 18.17±5.36 17.93±4.11 0.851
C3 17.27±3.94 18.17±5.03 0.449
C4 14.43±1.72 16.37±4.34 0.027*
>50000
34.5%
<50000
65.5%
Group B
<50000
70%
>50000
30%
Group A
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Total 74.03±12.29
73.97±11.5
4
0.983
Table 5: Comparison of mucositis
Mucositis
Group A
(n=30)
Group B
(n=30)
P value
Grade I 26 (86.7%) 23(76.7%) 0.317
Grade II 3(10.0%) 5(16.7%) 0.448
Grade III 1(3.3%) 2(6.7%) 0.554
Table 6: Comparison of Rise in Creatinine by more than 50.0% at 
48 hours
↑ Creatinine 
>50.0%
Group A
(n=120)
Group B
(n=120)
P value
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C1 1 2
C2 1 1
C3 0 1
C4 1 2
Number of 
episodes
3 (2.5%) 6(5%) 0.499
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0
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Table 7: Comparison of levels of serum Creatinine (mg/dl)
Phases
Levels of s.  
Creatinine
Group A
(n=30)
Group B
(n=30)
P value
C1
0 hour 0.59±0.12 0.60±0.09 0.555
48 hour 0.64±0.22 0.61±0.09 0.502
P value 0.265 0.745 -
C2
0 hour 0.59±0.09 0.59±0.11 1.000
48 hour 0.62±0.12 0.58±0.09 0.185
P value 0.211 0.620 -
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C3
0 hour 0.60±0.12 0.59±0.12 0.835
48 hour 0.59±0.09 0.77±0.99 0.327
P value 0.655 0.356 -
C4
0 hour 0.60±0.11 0.60±0.13 1.000
48 hour 0.59±0.11 0.63±0.15 0.246
P value 0.536 0.310 -
Table 8: Comparison of MTX >0.30 at 48 hours between two groups
MTX >0.30
Group A
(n=30)
Group B
(n=30)
P value
C1 2(6.7%) 0 0.492
C2 0 1(3.3%) 1.000
C3 0 2(6.7%) 0.492
C4 0 2(6.7%) 0.492
Number of 
episodes
2(1.7%) 5(4.2%) 0.446
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Table 9: Comparison of LFT Abnormalities
Any  bilirubin>1.4mg/dl,  SGOT/SGPT>2  times  upper  limit  of 
normal,i.e>80 u/l taken as LFT derangement
LFT high
Group A
(n=30)
Group B
(n=30)
P value
C1 5 (16.7%) 8(26.7%) 0.347
C2 5(16.7%) 5(16.7%) 1.000
C3 4(13.3%) 1(3.3%) 0.353
C4 3(10.0%) 3(10.0%) 1.000
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Table 9 a .Transaminitis post HDMTX
Transaminitis Grade 3 gm/m2 5 gm/m2
Grade 1 9 7
Grade 2 6 6
Grade 3 2 3
Grade 4 0 1
Table 10: Comparison of Total WBC Count (TC)
Phases Levels of TC
Group A
(n=30)
Group B
(n=30)
P value
C1
501-1000 - -
1001-1500 5 (16.7%) 6(20.0%)
1501-2000 1(3.3%) 3(10.0%)
>2000 24(80.0%) 21(70.0%)
χ2=0.800; 
P=0.371
C2
501-1000 1(3.3%) 2(6.7%)
1001-1500 5(16.7%) 6(20.0%)
1501-2000 1(3.3%) 3(10.0%)
>2000 23(76.7%) 18(60.0%)
χ2=1.926; 
P=0.165
C3
501-1000 1(3.3%) 2(6.7%)
1001-1500 6(20.0%) 5(16.7%)
1501-2000 1(3.3%) 2(6.7%)
>2000 22(73.3%) 21(70.0%)
χ2=0.082; 
P=1.000
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C4
501-1000 2(6.7%) 2(6.7%)
1001-1500 3(10.0%) 8(26.7%)
1501-2000 2(6.7%) 3(10.0%)
>2000 23(76.7%) 17(56.7%)
χ2=2.700; 
P=0.100
Table 11: Comparison of days taken for TC to recover
Phases Levels of REC
Group A
(n=30)
Group B
(n=30)
P value
C1
Before D14 26(86.7%) 26(86.7%) 1.000
D15-D18 2(6.7%) 2(6.7%) 1.000
D19-D22 1(3.3%) 1(3.3%) 1.000
D23-D26 0 0 -
D27-D30 1(3.3%) 1(3.3%) 1.000
C2
Before D14 23(76.7%) 21(70.0%) 0.559
D15-D18 3(10.0%) 6(20.0%) 0.472
D19-D22 3(10.0%) 2(6.7%) 1.000
D23-D26 1(3.3%) 1(3.3% 1.000
D27-D30 0 0 -
C3
Before D14 23(76.7%) 25(83.3%) 0.384
D15-D18 5(16.7%) 0 0.050*
D19-D22 2(6.7%) 4(13.3%) 0.671
D23-D26 0 0 -
D27-D30 0 1(3.3%) 1.000
C4
Before D14 28(93.3%) 24(80.0%) 0.254
D15-D18 0 2(6.7%) 0.492
D19-D22 2(6.7%) 0 0.492
D23-D26 0 3(10.0%) 0.237
D27-D30 0 1(3.3%) 1.000
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Table 12 Comparison of Thrombocytopenia
Thrombocytopenia Group A  (n=30) Group B (n=30)
Normal 19 (63.3%) 20(66.7%)
Grade 1 3(10.0%) 2(6.7%)
Grade 2 4(13.3%) 5(16.7%)
Grade 3 3(10.0%) 2(6.7%)
Grade 4 1(3.3%) 1(3.3%)
Table 13: Comparison of Febrile neutropenia
Febrile  
neutropenia
Group A
(n=30)
Group B
(n=30)
P value
C1 7(23.3%) 10(33.3%) 0.390
C2 8(26.7%) 5(16.7%) 0.347
C3 7(23.3%) 12(40.0%) 0.165
C4 6(20.0%) 4(13.3%) 0.488
Number of 
episodes
28(23.3%) 31(25.8%) 0.653
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Table 14: Comparison of Use of antibiotics
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Use of antibiotics
Group A
 (n=30)
Group B 
(n=30)
P value
C1 8 (26.7%) 8(26.7%) 1.000
C2 8(26.7%) 5(16.7%) 0.347
C3 7(23.3%) 14(46.7%) 0.058+
C4 6(20.0%) 4(13.3%) 0.488
Number of 
episodes
29(24.2%) 31(25.8%) 0.682
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Table 15: Comparison of number of days 6MP was given
No of days of 6MP Group A (n=30) Group B (n=30)
<20 3 (10.0%) 0
21-30 4(13.3%) 4(13.3%)
31-40 7(23.3%) 8(26.7%)
41-50 6(20.0%) 10(33.3%)
51-60 10(33.3%) 8(26.7%)
Mean ± SD 41.20±13.39 42.83±10.53
6MP administered in number of days is statistically similar between two 
groups with P=0.602 
Table 16.Central Nervous System Toxicity
AGE SEX HDMTX ITMTX DEFICIT Recover
y
CSF MRI RFT S.MTX
4 F D 11 D 12 Hemiparesis 1 day N N N 0.15
8 F D 9 D 9 Hemiparesis 1 day N N N 0.2
13 M D 10 D 10 Hemiparesis 2 days N N N 0.18
14 F D 12 D 12 Hemiparesis 3 days N N N 0.22
Table 17 Toxicities associated with HDMTX(including both groups)
Toxicity Number
(out of 240)
Percentage
Doubling of Creatinine 2 .9%
45
50 % rise in Creatinine at 48 
hours post HDMTX
9 3.75%
Mucositis Grade 2 or more 11 4.5%
Transaminitis Grade 2 or 
more
18 7.5%
Neutropenia Grade 2 or 
more
70 29%
Febrile Neutropenia 59 24.5%
Thrombocytopenia Grade 2 
or more
16 6.6%
Mean Number of days 
delayed
5.6 N.A.
Base Line Characteristics
The study population  was matched for age ( Table 1). Approximately 
60% % of the study population was less than 10 years of age. There was 
slight  male  preponderance  in   the  study  population(Table  2).  But  no 
stsistically  significant  difference  was  present  between the two groups 
with respect  to gender. Although both Total  WBC count and age are 
considered together for risk stratification, TC was separately considered 
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for matching and both there was no difference between two groups   
(Table 3).
Delay in completion of protocol was noted in both the groups. But the 
mean value of days taken was 74 days for both the groups (Table 4). 
There  was  no  significant  change  between  the  various  consolidation 
cycles.  Grade  1  mucositis  was  noted  in  majority  of  the  patients  
(Table 5). Number of patients with either Grade 2 or 3 mucositis was 
more in 5 gm/m2 group.
Renal Function Test Abnormality
Any increase in Serum Creatinine values post  HDMTX may point  to 
nephrotoxicity. Increase of  Creatinine by 50 % from the baseline value 
was compared.( Table 6).Group administered  5 gm/m2  had double the 
number  of  such  cases  (6  out  of  240  infusions)  when  compared  to  
3 gm/m2 group. No significant change was noticed between creatinine 
levels at  baseline and at 48 hours between the two groups. (Table 7). 
This remained the same throughout the continuation of protocol  from 
Consolidation cycle 1 through 4. Serum Methotrexate levels at 48 hours 
>0.3  micromol/L  was  noted  in  5  patients  administered  5  gm/m2 
HDMTX, (Table 8) which was more than 2 similar episodes noted in the 
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other group. But when taken as a side effect of 120 infusions in each, 
there was no statistical significance. 
Liver Function Test abnormalities
If  the total  study population is  taken,17 patients  each had some LFT 
abnormalities in either group. (Table 9 & 9a)Further analysed as number 
of  patients  having  Hyperilirubinemia,  and  transaminitis  .Isolated 
hyperbilirubinemia  (Bilirubin  >  1.4mg/dl)  was  seen  in  4  patients  in  
3 gm/m 2 group and 6 patients in 5 gm /m2 group. Maximum level was 
8 mg/dl%
Myelosuppression
Neutropenia
Was categorized into 4 grades.There was no case with TC les than 500. 
ANC was calculated ,but as ANC was not available for all cases, in order 
to  make  the  comparison  uniform  ,  total  WBC  count  was  taken  for 
analysis  (Table  10).  In  those  with  Grade  3  or  4  neutropenia  ,  no 
significant difference was noticed among Group A or B. Only less than 
5 % of the infusions was complicated by TC < 500.Growth factors were 
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used in  4 cases in 5 gm/m2 group. 
Recovery of counts
80-85%  of  the  patients  had  recovery  of  counts  with  in  14  days  of 
HDMTX. More than 4 days delay before the recovery of TC was seen in 
10 out of 120 infusions in 3 gm/m 2 and in 15 out of 120 infusions in 5 
gm/m2(Table  11).  Although  the  absolute  numbers  are  low,  this 
observation was statistically significant. 
Thrombocytopenia
21 episodes of thrombocytopenia of any grade was noticed in the study 
population. There was no significant difference between both the groups 
(10 in 3 gm/m2 and 11 in 5 gm/m2 (Table 12).2 patients in 5 gm/m2 
group had bleeding manifestations.7 platelet transfusions were given for 
Grade 3 & 4 thrombocytopenia.
Febrile neutropenia
Febrile neutropenia was noted in 23.3 % of 3 gm/m2 group and 25.8 % 
of 5 gm/m2 group,  which was not  statistically significant  (Table 13). 
.Documented infection was seen in 24% of febrile neutropenic episodes.. 
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Among  the  documented  infections  Gram-negative  organisms  were 
isolated 42.8 %. Organisms were mostly Escherechia coli, Kleibseilla, 
Pseudomonas  in  a  few  Acinetobacter.  Gram-positive  infections  were 
reported   in  32.3%.  Organisms  isolated  were  mostly  Staph.aureus, 
streptococci,  coagulase  negative  staphylococcus.  Antifungals  were 
started presumptively for 3 patients.  Antibiotics were used in 25% of 
infusions  in  both  groups  according to  the  hospital  policy(Table  14).  
5 days of antibiotics was sufficient for  80% of the cases.
Dose intensity of 6 MercaptoPurine
6 MP could be administered as per protocol in only  30 % of  the patients 
.The study population received a mean of 42 days of 6 MP(Table 15). 
There was no difference between 3 and 5 gm/m2 HDMTX  
CNS Toxicity
4 out of 120 5 gm/m2 HDMTX infusions were characterized by transient 
hemiparesis. All the patients had normal CSF studies upfront(Table 16). 
They  had  received  IT  MTX along  with  intravenous  high  dose  MTX 
(HDMTX) 5 gm/m2 before  the  event.  All  the patients  developed the 
event  between  Day  9  to  D12  of  HD MTX.   The  neurological  event 
recovered within 24 hours in all of them . CSF study was normal in all 
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patients  I/T MTX had been given for all.
Tolerability of HDMTX 
Significant  toxicities  which  were  observed  in  the  study  population 
including  both  the  groups  is  given  in   Table  17.Renal  dysfunction 
characterized  by  a  rise  in  serum  Creatinine  was  seen  in  only 
4.65%.Although mild mucositis was noted in majority, only 11 patients 
had grade 2 or above mucositis.Liver function tests were deranged post 
HDMTX in 7.5 % .Neutropenia was observed in 29% of  population .
25% of  the  infusions  were  complicated  by  fever  also.  Despite  these 
factors,the median delay before starting the next HDMTX was only 5.6 
days for both the groups combined together.  
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DISCUSSION
In  analyzing  outcome  for  acute  lymphoblastic  leukemia,   risk 
categorization according to age,total count,immunophenotyping and sex 
are some of the factors influencing outcome (2). Male sex is one of the 
poor prognostic factors in treatment of leukemia (3). When the toxicity 
profile of an agent is studied ,it is essential that they are matched for the 
above factors . In the study,patients  below age of 10 years was similar in 
both groups.
Dose intensity
Maintaining dose intensity is an important factor in deciding outcome in 
acute  lymphoblastic  leukemia.  This  was  particularly  important  in  this 
study as the tolerability of the study population was uncertain. As per the 
BFM 86 protocol, each High dose Methotrexate is to be given once in 14 
days.(12) Both  the groups took 74 days to complete the consolidation 
phase.  There  was  a  mean  delay  of  5.6  days  for  the  total  study 
population.In BFM 86 pilot study,the duration of consolidation phase is 
60-64 days.So the reason for the delays like mucositis,myelosuppression, 
transaminitis etc were analysed.
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Mucositis 
Mucositis  is  a  major  complication  in  all  protocols  which  utilize 
HDMTX.  (25)Various  reasons  like  inadequate  hydration,  elimination 
delay  of Methotrexate( 42),co administration of 6 MP are some of the 
aggravating factors. Grade 1 mucositis seen in the majority (81%) was a 
cause of concern, but did not lead to much treatment delays.
Renal Function Derangements
As MTX is  primarily cleared by  renal  excretion,  MTX-induced renal 
dysfunction  leads to  delayed  elimination  of  MTX,  and  the  resulting 
sustained, elevated plasma MTX concentration may lead to ineffective 
rescue by LV and a marked enhancement of MTX’s other toxicities like 
mucositis,myelosuppression  and  transaminitis(23,27).  Creatinine 
clearance was calculated only at the beginning of consolidation. A lack 
of  correlation between Creatinine  clearance  and methotrexate  toxicity 
has previously been reported (29).
The  majority  of  patients  with  renal  dysfunction are  initially 
asymptomatic, and most present with nonoliguric renal dysfunction(25). 
So  an  abrupt  rise  in  serum  creatinine during  or  shortly  after  MTX 
infusion indicates the development of renal dysfunction and can result in 
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significantly elevated plasma MTX concentrations Variations in serum 
Creatinine was further studied in both the groups, by taking the absolute 
values in each consolidation cycle .Elimination delay in Methotrexate 
has  been  described  as  one  of  the  factors  influencing  methotrexate 
toxicity.  (42).The  intent  was  to  analyse  whether  there  was  any 
progressive  decline  in  the  levels  with  repeated  infusions.   Both  the 
groups had a very close median baseline values of 0.59/0.60.There was 
no marked change in the values with the continuation of regimen, thus 
ascertaining  the  tolerability  of  HDMTX.  There  was  a  small  (<0.1) 
change in Creatinine after 48 hours in most of the cycles, which is of no 
significance. Only in 3 rd consolidation in group B was a trend towards 
significance seen, the baseline creatinine value being 0.59 and 48th hour 
Creatinine being 0.77. There is paucity of literature aboot worsening of 
Renal functions with successive HDMTX infusions.
Analysis of Methotrexate levels
Serum  MTX  levels  is  the  most  important  determining  toxicity  after 
HDMTX infusion (43).  The  values  have to  be done at  24,48 and 72 
hours.  Only 2 patients had values more than 1 mic mol/L at 48 hours. In 
order  to  correct  for  any  laboratory  variation  in  Mtx  assay,  a  lower 
threshold  of  0.3  mic  mo/L  at  48  hours  was  chosen  for  comparison 
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between the two groups. Only 2 patients( 1.7 % of all infusions)in group 
A and 5 patients( 4.2 % of all infusions) in Group B had MTX > 0.3 mic 
mol/L at  48 hours.  No progressive  derangement  was  noted  from C1-
C4.The difference between 2 groups was also not statistically significant.
Liver function tests abnormalities 
Post  HDMTX,  alterations  in  LFT  line  hyper  bilirubinemia  2 
transaminitis  can occur (32).  Elimination delay of MTX can result  in 
aggravation  of  LFT  abnormalities  (42).  Any  bilirubin  >  3  mg/dl 
necessitates a reduction in dose of MTX. MTX, 6MP and LV rescue can 
result  in  transaminitis.  However,  the  alterations  seen  in  the  study 
population  was  not  significant,  but  resulted  in  protocol  delay.  No 
episodes of encephalopathy were noted. Although supportive care helped 
in resolution of transaminitis, dose intensity was compromised as both 6 
MP had to be pended and there was a delay before initiation of the next 
cycle.
Myelosuppression  
Neutropenia
HDMTX is myeloablative and leucovorin rescue is mandatory (45). The 
dose of leucovorin is of importance, as studies have shown that increase 
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in  LV  dose  can  increase  the  incidence  of  relapse  (57).  As  noted  in 
previous studies (42), the incidence of TC < 2000 in the population with 
normal Methotrexate elimination as about 60-70%.Relling et all (24) has 
reported increased MTX area under the concentration time curve, low 
urine pH,emesis, intrathecal therapy and low Methotrexate clearance as 
various  factors  associated  with  increased  with  increased  methotrexate 
toxicity like myelosuppresion and mucositis (24).
Recovery of counts
Any delay in the recovery of counts will compromise dose intensity as 
well as make the patient susceptible to febrile neutropenia(33). 80% of 
the  patients  had  recovery  of  counts  with  in  14  days  of  HDMTX. 
Elimination  delay  of  Methotrexate  increases  myelotoxicity.  As  the 
number of patients with increased Methotrexate levels was per se very 
low ,analysis for myelotoxicity in this subgroup could not be done. The 
percentage  of  patients  having  delay  in  resuming  subsequent 
chemotherapy was similar to other studies( 24).
Thrombocytopenia
Correlation  between thrombocytopenia  and serum methotrexate  levels 
has been reported (47).Bleeding manifestations after HDMTX therapy is 
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seldom reported. Delayed methotrexate elimination has been found to be 
one of the risk factors for thrombocytopenia (42) .
Febrile neutropenia
The pattern  of  infections  associated  with  ALL therapy in  developing 
countries  are  different  from that  of  Western  literature.  There  is  still 
predominance  of gram negative infection unlike in the developed  where 
there  is  a  shift  to  gram  posititve  infection.(49).  The  gram  negative 
organisms  included  K.pneumoniae,  E  Coli  Ps.aeroginosa  and 
Acinetobacter.Infections  complications  during  intensive  phases  of 
treatment of acute lymphoblastic leukemia   has previously been reported 
(48).  25%  of  HDMTX  infusions  were  complicated  by  febrile 
neutropenia.This  is  comparable  with  the  Institute  data  of  febrile 
neutropenia in various protocols,i.e,MCP 841 and INCTR-02. 
Dose intensity of 6 Mercaptopurine 
Due  to  various  genetic  polymorphisms,  there  is  marked  variation  in 
mercaptopurine  metabolism.  This  has  been  found  to  affect  minimal 
residual  disease  and  outcome  in  ALL  (50,51).  Although  molecular 
studies were not done, dose intensity of 6 MP was analysed.75 % dose 
intensity could be maintained, and there was no significant difference 
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between the two groups.Mucositis,  transaminitis and neutropenia were 
the main reasons for pending 6 MP. 
Central Nervous System Toxicity
Subacute toxicities like seizures, cerebellar dysfunction and hemiparesis 
have  been  described  previously  (53).  Transient  hemiparesis  was  an 
unusual toxicity described in the study population.All the events were 
seen in 5 gm/m2 group.All of them were exposed to multiple doses of IT 
MTX prior  to  the  event.  There  was  definite  sex  predilection  for  this 
event with females being more affected. Interestingly the toxicity is seen 
around Day 9 to day 12. Despite the event HDMTX and IT MTX was 
continued in  all these patients but no recurrences were noted. Imaging 
studies were conducted in all patients within 24 hours of the onset of the 
event and all had normal standard MR imaging study of the brain. 
Prognostic Factors Predicting Toxicity
The plasma concentration of MTX after high-dose therapy was closely 
related to the renal excretion(14) the exposure to nephrotoxic agents, the 
age of the patients, the dosage of hydration, and the intensity of urine 
alkalization.(15)  Rask  et  al  reported  that  the  oral  mucositis  and  the 
elevated liver enzymes were related to the slow clearance or high area 
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under  curve(58).  Other  reports  concerning  raised  hematologic  side 
effects due to delay in methotrexate elimination  are also documented in 
the  literature  (59).  In  the  original  BFM  86  protocol  study  (12),  no 
difference in toxicity was noted among the patients given either 5 gm/m2 
or 8gm/m2 HDMTX. The same rationale holds good for the identical LV 
rescue  given  after  variable  doses  of  HDMTX.  After   matching  for 
confounding  factors,  data  was  analysed  for  any   variable  predicting 
HDMTX  toxicity.  As  the  number  of  infusions  complicated  by 
significant  toxicity  was  per  se  small  in  the  study  population,  no 
significant variable could be determined.
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CONCLUSIONS
 Adequate  hydration,  alkalanisation  and  Leucovorin  rescue  with 
close  monitoring  of  Serum Creatinine  as  well  as  Methotrexate 
levels are essential to prevent life threatening toxicities.
 High dose Methotrexate (HDMTX) could be safely administered 
across all age groups in the study population.
 Myelosuppression  and  febrile  neutropenia  resulted  in  treatment 
delays.
 Cumulative toxicity of HDMTX with repeated infusions was not 
noted.
  There was no significant difference in tolerability between 3 gm/
m2  and 5 gm/m2 of HDMTX.
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